Testosterone undecanoate parenteral - Bayer HealthCare Pharmaceuticals

Drug Profile

Testosterone undecanoate parenteral - Bayer HealthCare Pharmaceuticals

Latest Information Update: 22 Mar 2010

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypogonadism

Most Recent Events

  • 11 Jun 2009 Pharmacodynamics and adverse events data from a phase II trial in Hypogonadism presented at the 91st Annual Meeting of the Endocrine Society (ENDO-2009) ,
  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top